NCT07004582 Lab Research Using Mini-tumors to Study Prostate Cancer Treatments
| NCT ID | NCT07004582 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Maastricht Radiation Oncology |
| Condition | Prostate Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 600 participants |
| Start Date | 2026-03-15 |
| Primary Completion | 2031-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 600 participants in total. It began in 2026-03-15 with a primary completion date of 2031-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
For men with an aggressive form of prostate cancer, finding the right and effective treatment right away is challenging. Many of these men face a high risk of cancer recurrence: about half experience a relapse after surgery, and more than a third after undergoing radiation therapy. Men with metastatic prostate cancer have particularly poor prognoses, with a five-year survival rate of only 30% to 50%. In short, it is difficult to predict which treatment, or combination of treatments, will lead to longer survival for this group of men with aggressive (metastatic) prostate cancer. In the laboratory, it is possible to grow small samples of tumors into 3D mini-tumors. These mini-tumors retain the characteristics of the patient's original tumor tissue. Various treatments can be tested on these 3D mini-tumors to determine which therapy is most effective for each individual case. There are currently two techniques available for creating these 3D mini-tumors in the lab. In this project, we aim to investigate which of these two techniques works best in order to test and personalize treatments.
Eligibility Criteria
Inclusion Criteria: * Patients aged 18 years or older * Patients with prostate cancer * Patients planned for HDR brachytherapy treatment for high-risk or recurrent prostate cancer or transperineal prostate biopsy with MRI-suspected metastatic prostate cancer with at least clinical stage T3-4. Exclusion Criteria: * Patients younger than 18 years * Patients of whom it is not possible to obtain left-over tissue as part of the normal clinical treatment procedure (e.g., if all tumor material is required for the pathologist to make a diagnosis, to stage the patient or to perform a molecular diagnosis).
Contact & Investigator
Evert J Van Limbergen, PhD, MD
PRINCIPAL INVESTIGATOR
Maastricht Radiation Oncology
Frequently Asked Questions
Who can join the NCT07004582 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07004582 currently recruiting?
Yes, NCT07004582 is actively recruiting participants. Contact the research team at iris.laven@maastro.nl for enrollment information.
Where is the NCT07004582 trial being conducted?
This trial is being conducted at Heerlen, Netherlands, Maastricht, Netherlands, Maastricht, Netherlands.
Who is sponsoring the NCT07004582 clinical trial?
NCT07004582 is sponsored by Maastricht Radiation Oncology. The principal investigator is Evert J Van Limbergen, PhD, MD at Maastricht Radiation Oncology. The trial plans to enroll 600 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.